BioStem Technologies, Inc. (BSEM)
| Market Cap | 120.12M |
| Revenue (ttm) | 292.21M |
| Net Income (ttm) | 20.20M |
| Shares Out | 16.80M |
| EPS (ttm) | 0.85 |
| PE Ratio | 8.38 |
| Forward PE | 34.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 605,504 |
| Average Volume | 133,965 |
| Open | 5.35 |
| Previous Close | 5.29 |
| Day's Range | 5.30 - 7.20 |
| 52-Week Range | 3.09 - 19.28 |
| Beta | -0.10 |
| RSI | 72.31 |
| Earnings Date | Apr 13, 2026 |
About BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical pr... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
Accelerates expansion of BioStem's commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem's position across hosp...
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today anno...
BioStem Technologies, Inc. (BSEM) Q3 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Philip Taylor - Associate Jason Matuszewski - CEO, President, Secretary & Chairman Bran...
BioStem Technologies Reports Third Quarter 2025 Financial Results
POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Announces Filing of Restated Financial Statements
POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today comm...
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
POMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and com...
BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025
POMPANO BEACH, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program
Program has honored more than 500 members of the military since its inception Sponsorship honors both local military veterans and healthcare professionals POMPANO BEACH, Fla., Oct. 02, 2025 (GLOBE NEW...
BioStem Technologies, Inc. (BSEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
BioStem Technologies, Inc. (OTCPK:BSEM) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 3:20 PM EDT Company Participants Jason Matuszewski - CEO, President, Secretary & Chai...
BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting
Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem's proprietary allogra...
BioStem Technologies to Present at Two Upcoming Investor Conferences
POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Corporate Participant Brandon Poe - Corporate Participant Jas...
BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and com...
BioStem Technologies Appoints Brandon Poe as Chief Financial Officer
POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and com...
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET
POMPANO BEACH, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies: Huge Growth, Poised To Help Wound Care Field
BioStem Technologies is a buy due to strong YoY growth, profitability, and undervaluation versus sector peers despite recent Q1 misses. Their advanced wound care products, powered by proprietary BioRE...
Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist
POMPANO BEACH, Fla., May 22, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and comm...
BioStem Technologies, Inc. (BSEM) Q1 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Adam Holdsworth - Director-Investor Relations Jason Matuszewski - Chief Executive ...